RDX and prostate carcinoma: In the non-type molecular subtype, TLN1 is significantly hyperphosphorylated at S425 in the head domain (band 4.1, ezrin, radixin, moesin homology domain) (Supplementary Figure S5), a site also known to be hyperphosphorylated in prostate cancer [39].